# Treatment methods for Huntington's disease
Huntington's disease is currently treated using an approach that focuses on alleviating symptoms and exploring possibilities to slow the underlying disease processes. There is no cure that stops or reverses the condition, but treatments help many people remain functional longer.
Movement disorders (involuntary movements)
**Tetrabenazine**
ProveniIncluded in official guidelines, or approved by EMA or FDA
This medication reduces the amount of dopamine in certain brain regions, thereby decreasing involuntary movements (chorea). It works by inhibiting vesicular monoamine transporters, so that movement signals are transmitted less excessively. Many patients benefit from reduced spastic movements and better balance.
Known side effects are fatigue, depression, and lower blood pressure (especially when standing up). Some people also experience noticeable slowing of their thoughts. These effects require regular monitoring and dosing under supervision.
**Deutetrabenazine**
ProveniIncluded in official guidelines, or approved by EMA or FDA
This is a substance similar to tetrabenazine, but works slightly differently in the body (longer-acting and fewer side effects reported in some studies). It also helps with chorea. Studies are currently investigating how it affects speech and gait.
Side effects appear similar in profile to tetrabenazine: fatigue, mood changes, and sometimes low blood pressure. Ongoing supervision is also necessary here.
**Antipsychotics (haloperidol, risperidone, aripiprazole)**
ProveniIncluded in official guidelines, or approved by EMA or FDA
This class of medications inhibits dopamine activity in the brain at a different level than tetrabenazine. They are used when tetrabenazine works insufficiently, is not well tolerated, or is associated with certain psychiatric symptoms. They can reduce movements and at the same time reduce impulsive behavior.
Side effects vary by medication. Slow, involuntary movements (tardive dyskinesia) can occur with long-term use. Weight gain, blood sugar abnormalities, and neurological blunting have also been reported. The doctor chooses carefully, weighed against benefit.
---
Psychiatric symptoms
**Selective serotonin reuptake inhibitors (SSRIs)**
ProveniIncluded in official guidelines, or approved by EMA or FDA
These are antidepressants that keep serotonin available in the brain. They are used for depression, obsessive thoughts, and anxiety that commonly occur in Huntington's disease. They work by releasing substances that affect mood and anxiety.
Side effects can include: gastrointestinal complaints, insomnia or conversely drowsiness, and sometimes sexual side effects. They typically do not work immediately; effects develop over weeks to months.
**Other psychopharmaceuticals (mirtazapine, bupropion, amitriptyline)**
ProveniIncluded in official guidelines, or approved by EMA or FDA
These medications work via different routes on the brain and are used for depression, anxiety disorders, or sleep problems, depending on what the patient experiences. They are traditional, with long clinical experience.
All have their own profile of possible side effects: drowsiness, dry mouth, weight changes, and more rarely heart or blood pressure effects. A doctor will make the best choice for the individual situation.
---
Cognitive symptoms and fatigue
**No standard pharmacological treatment (consensus)**
ResearchediPositive results in clinical studies, not yet standard treatment
To date, no medication with high evidence level has been demonstrated to improve memory, attention, or concentration in Huntington's disease. Research is ongoing into medications that might help with cellular dysfunction (such as interventions targeting mitochondrial function and autophagy processes), but these are not yet included in standard practice.
Cognitive training and physical exercise are being studied as supportive measures; they help some people maintain mental functions better, but do not produce medication-like effects.
---
Disease-modifying approaches (research)
**Gene therapy and nucleic acid techniques**
ResearchediPositive results in clinical studies, not yet standard treatment
Research is investigating agents that directly target the mutation in the huntingtin gene, for example through antisense oligonucleotides or RNA interference. The goal is to reduce the production of harmful protein. Some candidates are in Phase 3 studies.
This approach is promising because it addresses the core of the disease process. Side effects are still under investigation, but may include neurotoxicity, redistribution in the body, and immune reactions.
**Pridopidine**
ResearchediPositive results in clinical studies, not yet standard treatment
This agent affects signaling molecules in the brain (including sigma-1 receptors) and may help prevent neural damage. Phase 3 studies are investigating whether it can slow the progression of motor and functional decline.
To date, side effects in studies have been reported as mild (headache, nausea), but more data are being collected as research progresses.
**Votemtamab (RG6496)**
ResearchediPositive results in clinical studies, not yet standard treatment
This is an agent that may support glial cell differentiation. Studies are investigating safety and efficacy in Huntington's disease. It could potentially help improve cellular metabolism in damaged brain regions.
Data on side effects are limited; studies are ongoing.
**Votoplam**
ResearchediPositive results in clinical studies, not yet standard treatment
This agent targets metabolic processes in the cell, specifically anaplerosis (replenishment of energy carriers). Studies are investigating whether it can reduce oxidative stress and slow neurodegenerative processes.
Research is ongoing; side effects are still being inventoried.
---
Additional supportive measures
**Physiotherapy and rehabilitation**
ProveniIncluded in official guidelines, or approved by EMA or FDA
Regular physical exercise, balance training, and targeted exercises help slow the loss of motor control. Physiotherapy can prevent falls, improve balance, and maintain muscle strength. This is especially important as the disease progresses.
No direct medication side effects, but fatigue may occur with intensive training.
**Speech and language pathology (speech and swallowing therapy)**
ProveniIncluded in official guidelines, or approved by EMA or FDA
Many patients gradually lose speech clarity and develop swallowing difficulties. Speech and language pathology helps teach compensation techniques and makes eating safer. This prevents malnutrition and aspiration pneumonia.
No pharmacological side effects.
**Diet and nutrition**
ProveniIncluded in official guidelines, or approved by EMA or FDA
Patients often need more calories due to hyperkinetic movements. Good nutritional advice and tube feeding (where necessary) help counteract weight loss. Good nutrition supports the immune system and brain tissue.
No medication side effects, but adaptation to technical support may be needed.
---
Research areas without standard treatment
**Microbiota modulation**
ResearchediPositive results in clinical studies, not yet standard treatment
Recent research shows that gut flora in patients with Huntington's disease is altered, with differences between disease stages. Researchers are investigating whether adjusting the microbiota through probiotics, diet, or other agents can relieve symptoms. This is still experimental and not incorporated into clinical practice.
**Mitochondrial and oxidative stress targeting**
ResearchediPositive results in clinical studies, not yet standard treatment
The disease process in Huntington's disease is strongly linked to damage to mitochondria (the energy centres of cells) and excessive oxidative stress. Various studies are testing agents that can address these processes. This is still laboratory and early-phase clinical research.
**Amyloid-targeting peptides**
ExperimentaliOngoing in study setting, outcome still unknown
New classes of peptides (such as those in Fibrilpaint studies) are being tested for their ability to counteract abnormal protein aggregates in the brain. This is in a very early stage.
---
Treatment of complications
**Antiepileptic drugs**
ProveniIncluded in official guidelines, or approved by EMA or FDA
Some patients experience seizures; standard antiepileptic drugs are used to prevent or control these.
**Cardiac medications (where cardiac symptoms develop)**
ProveniIncluded in official guidelines, or approved by EMA or FDA
Research shows that cardiac arrhythmias and certain cardiometabolic abnormalities occur more frequently. Standard cardiac medications are used where necessary.
---
_This information never replaces a doctor's judgment. Always discuss your situation with your own healthcare provider._